3763-80-2

Usage

Uses

Used in Pharmaceutical Industry:
3-(2-chloro-10H-phenothiazin-10-yl)propan-1-amine is used as an antipsychotic agent for the treatment of schizophrenia and other mental disorders. It is effective in managing the symptoms of psychosis by antagonizing dopamine receptors in the brain.
Used in Treatment of Nausea and Anxiety:
In the pharmaceutical industry, 3-(2-chloro-10H-phenothiazin-10-yl)propan-1-amine is utilized as an antiemetic and anti-anxiety medication, making it beneficial for patients suffering from nausea and anxiety disorders. Its properties help alleviate the discomfort associated with these conditions.

Upstream product

• 180388-71-0 N-[3-(2-chloro-phenothiazin-10-yl)-propyl]-phthalimide 
• 92-39-7 2-chlorophenothiazine 

Downstream Products

• 22724-19-2 N-[3-(2-chloro-phenothiazin-10-yl)-propyl]-N-(toluene-4-sulfonyl)-acetamide 
• 1423077-24-0 4-chloro-N-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)benzenesulfonamide 
• 1423077-22-8 N-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-4-cyanobenzenesulfonamide 
• 1423077-16-0 N-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-4-methoxybenzenesulfonamide 
• 96178-10-8 5-ethyl-1-(3-phenothiazin-10-yl-propyl)-5-phenyl-pyrimidine-2,4,6-trione 
• 96068-57-4 1-[3-(2-chloro-phenothiazin-10-yl)-propyl]-5-ethyl-5-phenyl-pyrimidine-2,4,6-trione 
• 19077-27-1 N-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)-4-methylbenzenesulfonamide 

Relevant academic research and scientific papers

Reengineered tricyclic anti-cancer agents

The phenothiazine and dibenzazepine tricyclics are potent neurotropic drugs with a documented but underutilized anti-cancer side effect. Reengineering these agents (TFP, CPZ, CIP) by replacing the basic amine with a neutral polar functional group (e.g., RTC-1, RTC-2) abrogated their CNS effects as demonstrated by in vitro pharmacological assays and in vivo behavioral models. Further optimization generated several phenothiazines and dibenzazepines with improved anti-cancer potency, exemplified by RTC-5. This new lead demonstrated efficacy against a xenograft model of an EGFR driven cancer without the neurotropic effects exhibited by the parent molecules. Its effects were attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling.